CEO of Sequenom Inc. (
) Harry F. Hixson Jr. bought 50,000 shares on 08/01/2012 at an
average price of $2.92. The total transaction amount is $146,000.
Sequenom Inc. is in the field of industrial genomics. Sequenom
Inc. has a market cap of $367.7 million; its shares were traded
at around $3.05 with and P/S ratio of 6.6. Sequenom Inc. had an
annual average earnings growth of 14.5% over the past five years.
Aside from the company's CEO, Sequenom CFO Paul Maier also
purchased 10,000 shares of the company on 8/1/2012 at the average
price of $2.86. Various other insiders, including Executive Vice
President Ronald Lindsay and Director John Fazio, also have
increased their positions in the company in recent months.
Mr. Harry F. Hixson Jr., Ph.D., has been CEO of Sequenom Inc.
since Sept. 28, 2009 and previously served as its Interim CEO.
Dr. Hixson co-founded BrainCells Inc. and served as its CEO from
July 2004 to September 2005. He served as the CEO of Elitra
Pharmaceuticals Inc. from February 1998 to May 2003 and served as
its president from June 1998 to May 2003.
SQNM has an average annual revenue growth of -17.7% for the past
10 years, and an average revenue growth of -11.1% during the last
12 months. Earnings per share have been all negative during the
past 10 years, although figures have improved throughout the
years. The company holds $84.28 million in cash, and owes $13.27
million in long-term debt. Sequeonom has a predictability rating
of 1 star.
No gurus currently hold any position in SQNM.
About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to